332 related articles for article (PubMed ID: 32563850)
21. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
22. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity.
Jiang PL; Lin HJ; Wang HW; Tsai WY; Lin SF; Chien MY; Liang PH; Huang YY; Liu DZ
Acta Biomater; 2015 Jan; 11():356-67. PubMed ID: 25242652
[TBL] [Abstract][Full Text] [Related]
23. Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.
Tada R; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2018 Jul; 11(1):472. PubMed ID: 30005702
[TBL] [Abstract][Full Text] [Related]
24. Intranasal Administration of
Wang Y; An EK; Kim SJ; You S; Jin JO
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638944
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
26. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
Hattori Y; Kawakami S; Lu Y; Nakamura K; Yamashita F; Hashida M
J Gene Med; 2006 Jul; 8(7):824-34. PubMed ID: 16625665
[TBL] [Abstract][Full Text] [Related]
27. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model.
Vasievich EA; Ramishetti S; Zhang Y; Huang L
Mol Pharm; 2012 Feb; 9(2):261-8. PubMed ID: 22142394
[TBL] [Abstract][Full Text] [Related]
28. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine.
Tateshita N; Miura N; Tanaka H; Masuda T; Ohtsuki S; Tange K; Nakai Y; Yoshioka H; Akita H
J Control Release; 2019 Sep; 310():36-46. PubMed ID: 31386869
[TBL] [Abstract][Full Text] [Related]
29. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice.
Bei R; Guptill V; Masuelli L; Kashmiri SV; Muraro R; Frati L; Schlom J; Kantor J
J Immunother; 1998 May; 21(3):159-69. PubMed ID: 9610907
[TBL] [Abstract][Full Text] [Related]
30. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2014 Sep; 35(28):8186-96. PubMed ID: 24969637
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
[TBL] [Abstract][Full Text] [Related]
33. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth.
Whitmore M; Li S; Huang L
Gene Ther; 1999 Nov; 6(11):1867-75. PubMed ID: 10602382
[TBL] [Abstract][Full Text] [Related]
34. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses.
Whitmore MM; Li S; Falo L; Huang L
Cancer Immunol Immunother; 2001 Dec; 50(10):503-14. PubMed ID: 11776372
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines.
Yan W; Chen W; Huang L
Mol Immunol; 2007 Jul; 44(15):3672-81. PubMed ID: 17521728
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant-Enhanced mRNA Vaccines.
Bialkowski L; Van der Jeught K; Renmans D; van Weijnen A; Heirman C; Keyaerts M; Breckpot K; Thielemans K
Methods Mol Biol; 2017; 1499():179-191. PubMed ID: 27987150
[TBL] [Abstract][Full Text] [Related]
37. Liposome-mediated DNA vaccination: the effect of vesicle composition.
Perrie Y; Frederik PM; Gregoriadis G
Vaccine; 2001 Apr; 19(23-24):3301-10. PubMed ID: 11312029
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors.
Sun QF; Zhao XN; Peng CL; Hao YT; Zhao YP; Jiang N; Xue H; Guo JZ; Yun CH; Cong B; Zhao XG
Oncol Rep; 2015 Nov; 34(5):2289-95. PubMed ID: 26323510
[TBL] [Abstract][Full Text] [Related]
39. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier.
Cui Z; Han SJ; Vangasseri DP; Huang L
Mol Pharm; 2005; 2(1):22-8. PubMed ID: 15804174
[TBL] [Abstract][Full Text] [Related]
40. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
